دورية أكاديمية
أعرض في EDS

Elucidating the role of blood metabolites on pancreatic cancer risk using two-sample Mendelian randomization analysis.

التفاصيل البيبلوغرافية
العنوان: Elucidating the role of blood metabolites on pancreatic cancer risk using two-sample Mendelian randomization analysis.
المؤلفون: Zhong H; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA., Liu S; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA., Zhu J; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA., Xu TH; Torrey Pines High School, San Diego, California, USA., Yu H; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA., Wu L; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
المصدر: International journal of cancer [Int J Cancer] 2024 Mar 01; Vol. 154 (5), pp. 852-862. Date of Electronic Publication: 2023 Oct 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
مواضيع طبية MeSH: Pancreatic Neoplasms*/genetics , Carcinoma, Pancreatic Ductal*/genetics, Humans ; Mendelian Randomization Analysis ; Genome-Wide Association Study ; Longitudinal Studies ; Canada/epidemiology
مستخلص: Pancreatic ductal adenocarcinoma (PDAC) is an uncommon but highly fatal malignancy. Identifying causal metabolite biomarkers offers an opportunity to facilitate effective risk assessment strategies for PDAC. In this study, we performed a two-sample Mendelian randomization (MR) study to characterize the potential causal effects of metabolites in plasma on PDAC risk. Genetic instruments were determined for a total of 506 metabolites from one set of comprehensive genome-wide association studies (GWAS) involving 913 individuals of European ancestry from the INTERVAL/EPIC-Norfolk cohorts. Another set of genetic instruments was developed for 483 metabolites from an independent GWAS conducted with 8299 individuals of European ancestry from the Canadian Longitudinal Study on Aging (CLSA) cohort. We analyzed GWAS data of the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4), comprising 8275 PDAC cases and 6723 controls of European ancestry. The association of metabolites with PDAC risk was assessed using the inverse-variance weighted (IVW) method, and complemented with sensitivity analyses of MR-Egger and MR-PRESSO tests. Potential side effects of targeting the identified metabolites for PDAC intervention were further evaluated by a phenome-wide MR (Phe-MR) analysis. Forty-four unique metabolites were identified to be significantly associated with PDAC risk, of which four top-ranking metabolites (X: 12798, X: 11787, X: 11308 and X: 19141) showed replication evidence when using instruments developed from both two cohorts. Our results highlight novel blood metabolites related to PDAC risk, which may help prioritize metabolic features for PDAC mechanistic research and further evaluation of their potential role in PDAC risk assessment.
(© 2023 UICC.)
References: Int J Cancer. 2023 Jul 1;153(1):103-110. (PMID: 36757187)
J Proteome Res. 2015 Feb 6;14(2):1195-202. (PMID: 25429707)
Nat Genet. 2018 Sep;50(9):1335-1341. (PMID: 30104761)
PLoS Genet. 2009 Jun;5(6):e1000529. (PMID: 19543373)
Am J Epidemiol. 2013 Aug 15;178(4):534-42. (PMID: 23788672)
Ann Oncol. 2012 Jul;23(7):1880-8. (PMID: 22104574)
Cancer Lett. 2014 Apr 10;345(2):203-9. (PMID: 23981573)
Angew Chem Int Ed Engl. 2023 May 2;62(19):e202213703. (PMID: 36617502)
Adv Exp Med Biol. 2018;1063:131-145. (PMID: 29946781)
Fitoterapia. 2014 Dec;99:307-17. (PMID: 25454462)
Nat Med. 2014 Oct;20(10):1193-1198. (PMID: 25261994)
Nat Genet. 2023 Jan;55(1):44-53. (PMID: 36635386)
Cancer Causes Control. 2010 Aug;21(8):1213-25. (PMID: 20373013)
Nat Genet. 2016 Oct;48(10):1279-83. (PMID: 27548312)
Hum Mol Genet. 2018 Mar 15;27(6):1106-1121. (PMID: 29325019)
J Natl Cancer Inst. 2019 Apr 1;111(4):372-379. (PMID: 30137376)
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2079-2087. (PMID: 34497089)
Nat Commun. 2018 Feb 8;9(1):556. (PMID: 29422604)
Cancer Biol Ther. 2021 Jun 3;22(5-6):347-356. (PMID: 34224317)
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2735-2739. (PMID: 32967863)
Int J Epidemiol. 2016 Jun;45(3):908-15. (PMID: 27427429)
Alzheimers Dement (N Y). 2021 Mar 03;7(1):e12148. (PMID: 33718584)
Prog Lipid Res. 2003 May;42(3):238-56. (PMID: 12689619)
Bioinformatics. 2019 Nov 1;35(22):4851-4853. (PMID: 31233103)
JAMA Oncol. 2020 Oct 1;6(10):e202948. (PMID: 32789511)
Cancer Biol Ther. 2015;16(5):714-23. (PMID: 25996841)
J Agric Food Chem. 2019 Dec 4;67(48):13269-13281. (PMID: 31725275)
Psychol Med. 2017 Apr;47(5):971-980. (PMID: 27928975)
Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253)
Nat Genet. 2018 May;50(5):693-698. (PMID: 29686387)
Adv Exp Med Biol. 2018;1063:73-81. (PMID: 29946776)
Int J Epidemiol. 2019 Jun 1;48(3):795-806. (PMID: 30277539)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Nature. 2013 Apr 4;496(7443):101-5. (PMID: 23535601)
Nat Med. 2022 Nov;28(11):2321-2332. (PMID: 36357675)
Cancer Res. 2020 Oct 15;80(20):4346-4354. (PMID: 32907841)
Exp Mol Med. 2016 Mar 11;48:e219. (PMID: 26964835)
Gut. 2020 Nov;69(11):2008-2015. (PMID: 32060129)
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42. (PMID: 20133848)
Cell. 2012 Apr 27;149(3):656-70. (PMID: 22541435)
Pancreatology. 2011;11(6):574-84. (PMID: 22213040)
Exp Mol Med. 2019 Nov 29;51(11):1-11. (PMID: 31784505)
Bioinformatics. 2021 May 5;37(5):728-730. (PMID: 32898220)
معلومات مُعتمدة: R00 CA218892 United States CA NCI NIH HHS; T32 DK137523 United States DK NIDDK NIH HHS; U54 HG013243 United States HG NHGRI NIH HHS; R00CA218892 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: pancreatic ductal adenocarcinoma; plasma metabolites; risk; two-sample Mendelian randomization
تواريخ الأحداث: Date Created: 20231020 Date Completed: 20240105 Latest Revision: 20240526
رمز التحديث: 20240526
مُعرف محوري في PubMed: PMC10843029
DOI: 10.1002/ijc.34771
PMID: 37860916
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0215
DOI:10.1002/ijc.34771